Skip to content

Cyclosporin A Therapy in Childhood Nephrotic Syndrome

A Descriptive Study on the Effectiveness and Safety of Cyclosporin A Therapy in Steroid Dependent and Steroid Resistant Childhood Nephrotic Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03219684
Enrollment
50
Registered
2017-07-17
Start date
2018-04-01
Completion date
2019-08-01
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Steroid Dependent and Steroid Resistent Nephrotic Syndrome

Brief summary

Nephrotic syndrome (NS) is among the most common pediatric kidney diseases and is defined as massive proteinuria (\>40 mg/m2/h or urine protein to creatinine ratio \>2 g/g) leading to hypoalbuminemia (\<2.5 g/dL), edema, and hyperlipidemia. 60-70 % of patients present prior to age of 6 years

Detailed description

. Most children with NS are treated initially with oral corticosteroids, and they can be clinically classified based on their ability to achieve remission (i.e., complete normalization of proteinuria). Approximately 85 % of children under the age of 6 years are steroid-sensitive, whereas the remainder have steroid-resistant disease. Older children are more likely to have steroid-resistant NS. Children with steroid-resistant disease may have an underlying genetic cause for NS, and providers should consider genetic testing in this population, depending on the age of the child . While inherited causes of NS are often resistant to all therapies, there are reports of complete or partial remission in some children . For those children who respond to steroids, the majority will have one or more relapses and half will have frequently relapsing (≥4 relapses/year) or steroid-dependent (two consecutive relapses during steroid therapy or within 14 days of stopping steroids). NS Children with frequently relapsing NS and steroid-dependent NS may have significant side effects from cumulative corticosteroid therapy so treatment with other agents is often required . Cyclosporine and tacrolimus are calcineurin inhibitors that are commonly used as immunosuppressive agents in solid organ transplantation. CNIs are recommended as first-line therapy for children with steroid-resistant NS and as steroid-sparing agents for children with frequently relapsing or steroid-dependent NS .Calcineurin inhibitors (CNIs) inhibit T-cell activation and may be exerting their effect in nephrotic syndrome through this mechanism. Alternately, cyclosporine has been shown to directly target the podocyte and stabilize the actin cytoskeleton responsible for maintaining cell shape(5) .. Although the majority of studies in nephrotic syndrome have been performed with cyclosporine, tacrolimus appears to be equally efficacious. Cyclosporin A therapy is well recognised regarding its steroid sparing effect in steroid dependant patients and is responsible for maintaining remission in more than 75% of patients with Steroid dependent nephrotic syndrome even after discontinuation of steroids Furthermore, it has been shown to be effective in inducing remission in steroid resistant nephrotic syndrome. However ,Cyclosporin A is associated with a plethora of side effects such as hypertension, nephrotoxicity hypertrichosis, gum hyperplasia, gastrointestinal disturbances and tremor.

Interventions

DIAGNOSTIC_TESTserum protein ,kidney function ,liver function.,serum cholesterol

monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years

Inclusion criteria

* The study will include all children (on cyclosporine therapy for treatment of Steroid dependent or Steroid resistant nephrotic syndrome ) who present to Nephrology Unit , and clinic at Assiut University Children Hospital during one year duration.

Exclusion criteria

* children with adequate response to steroid therapy and without relapses or resistance to steroid therapy

Design outcomes

Primary

MeasureTime frameDescription
evaluation of nephrotic state of each patient for evaluation of efficacy of cyclosporin A therapyone yearmeasurment of serum albumin ,serum cholesterol and urinary protien excretion
evaluation of side effects of cyclosporin Aone yearserial observation of common side effects of cyclosporin A as hypertension, nephrotoxicity hypertrichosis, gum hyperplasia, gastrointestinal disturbances and tremor.

Contacts

Primary ContactMuhammed Mahrous, MD
eltellawy270@hotmail.com01003486595
Backup ContactAhlam Badawy
dr.ahlam_ali@yahoo.com01006807866

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026